Essential thrombocythemia: Scientific advances and current practice

Current Opinion in Hematology

Volumn 13, Issue 2, 2006, Pages 93-98

  Tefferi, Ayalew ^a  

^a MAYO CLINIC   (United States)

Author keywords

Diagnosis; Hydroxyurea; JAK2; Thrombocythemia; Treatment

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA INTERFERON; ANAGRELIDE; ANTITHROMBOCYTIC AGENT; HEMOGLOBIN; HYDROXYUREA; JANUS KINASE 2; PIPOBROMAN;

AGE; BLEEDING; CLINICAL TRIAL; CLONAL VARIATION; CYTOGENETICS; DISEASE COURSE; DRUG CHOICE; DRUG EFFICACY; FIBROSIS; GENE; GENE MUTATION; HIGH RISK PATIENT; HUMAN; JAK2 GENE; LEUKEMIA; LEUKOCYTE COUNT; MYELOPOIESIS; MYELOPROLIFERATIVE DISORDER; NEUTROPHIL; PHENOTYPE; POLYCYTHEMIA; PRIORITY JOURNAL; REVIEW; SURVIVAL; THROMBOGENESIS; THROMBOSIS; THROMBOTIC THROMBOCYTOPENIC PURPURA;

ANTINEOPLASTIC AGENTS; ASPIRIN; BONE MARROW EXAMINATION; HUMANS; HYDROXYUREA; IN SITU HYBRIDIZATION, FLUORESCENCE; JANUS KINASE 2; PLATELET AGGREGATION INHIBITORS; POINT MUTATION; THROMBOCYTHEMIA, ESSENTIAL; THROMBOCYTHEMIA, HEMORRHAGIC; THROMBOSIS;

EID: 33646786143     PISSN: 10656251     EISSN: 15317048     Source Type: Journal    
DOI: 10.1097/01.moh.0000208470.86732.b4     Document Type: Review

References (48)

1. Epstein E, Goedel A. Hemorrhagic thrombocythemia with a vascular, sclerotic spleen [in German]. Virchows Archiv A Pathol Anat Histopathol 1934; 293:233.
2. Dameshek W. Some speculations on the myeloproliferative syndromes. Blood 1951; 6:372-375.
3. Gunz FW. Hemorrhagic thrombocythemia: a critical review. Blood 1960; 15:706-723.
4. Fialkow PJ, Faguet GB, Jacobson PJ, et al. Evidence that essential thrombocythemia is a clonal disorder with origin in a multipotent stem cell. Blood 1981; 58:916-919.
5. Vardiman JW, Brunning RD, Harris NL. WHO histological classification of chronic myeloproliferative diseases. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, editors. World Health Organization classification of tumours: tumours of the haematopoietic and lymphoid tissues. Lyon, France: International Agency for Research on Cancer (IARC) Press; 2001. pp. 17-44.
6. Ruggeri M, Tosetto A, Frezzato M, Rodeghiero F. The rate of progression to polycythemia vera or essential thrombocythemia in patients with erythrocytosis or thrombocytosis. Ann Intern Med 2003; 139:470-475.
7. Lengfelder E, Hochhaus A, Kronawitter U, et al. Should a platelet limit of 600 x 10(9)/l be used as a diagnostic criterion in essential thrombocythaemia? An analysis of the natural course including early stages. Br J Haematol 1998; 100:15-23.
8. Sacchi S, Vinci G, Gugliotta L, et al. Diagnosis of essential thrombocythemia at platelet counts between 400 and 600 x 10(9)/L. Gruppo Italiano Malattie Mieloproliferative Croniche(GIMMC) Haematologica 2000; 85:492-495.
9. Harrison CN, Gale RE, Machin SJ, Linch DC. A large proportion of patients with a diagnosis of essential thrombocythemia do not have a clonal disorder and may be at lower risk of thrombotic complications. Blood 1999; 93:417-424.
10. Antonioli E, Guglielmelli P, Pancrazzi A, et al. Clinical implications of the JAK2 V617F mutation in essential thrombocythemia. Leukemia 2005; 19:1847-1849. An important study that demonstrated molecular evidence of clonality in essential thrombocythemia considered to be 'polyclonal' by X-linked clonality assays.
11. V617F-induced erythrocytosis in mice.
12. Tefferi A, Gilliland DG. The JAK2V617F tyrosine kinase mutation in myeloproliferative disorders: status report and immediate implications for disease classification and diagnosis. Mayo Clin Proc 2005; 80:947-958.
13. Saharinen P, Vihinen M, Silvennoinen O. Autoinhibition of Jak2 tyrosine kinase is dependent on specific regions in its pseudokinase domain. Mol Biol Cell 2003; 14:1448-1459.
14. V617F as it pertains to global as well as specific gene expression characteristics in polycythemia vera.
15. Goerttler PS, Steimle C, Marz E, et al. The Jak2V617F mutation, PRV-1 overexpression and EEC formation define a similar cohort of MPD patients. Blood 2005; 106:2862-2864.
16. V617F in MDS and atypical MPDs.
17. V617F in atypical MPDs.
18. V617F-associated clonal myeloproliferation. The study also confirms previous observations regarding the absence of the mutant molecule in T lymphocytes.
19. Levine RL, Loriaux M, Huntly BJ, et al. The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia. Blood 2005; 106:3377-3379.
20. Jelinek J, Oki Y, Gharibyan V, et al. JAK2 mutation 1849G > T is rare in acute leukemias but can be found in CMML, Philadelphia-chromosome negative CML and megakaryocytic leukemia. Blood 2005; 106:3370-3373.
21. V617F in essential thrombocythemia. The study showed that patients with the mutation display higher hemoglobin and leukocyte counts but they are not at more risk for either thrombosis or transformation into acute leukemia or myelofibrosis.
22. Steensma DP, Tefferi A. Cytogenetic and molecular genetic aspects of essential thrombocythemia. Acta Haematol 2002; 108:55-65.
23. Michiels JJ, Berneman Z, Schroyens W, et al. Philadelphia (Ph) chromosome-positive thrombocythemia without features of chronic myeloid leukemia in peripheral blood: natural history and diagnostic differentiation from Ph-negative essential thrombocythemia. Ann Hematol 2004; 83:504-512.
24. Damaj G, Delabesse E, Le Bihan C, et al. Typical essential thrombocythaemia does not express bcr-abelson fusion transcript. Br J Haematol 2002; 116:812-816.
25. Elliott MA, Tefferi A. Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia. Br J Haematol 2005; 128:275-290.
26. Barbui T, Barosi G, Grossi A, et al. Practice guidelines for the therapy of essential thrombocythemia. A statement from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. Haematologica 2004; 89:215-232.
27. Falanga A, Marchetti M, Vignoli A, et al. Leukocyte-platelet interaction in patients with essential thrombocythemia and polycythemia vera. Exp Hematol 2005; 33:523-530. A study that incriminates neutrophils as being thrombogenic in essential thrombocythemia.
28. Cortelazzo S, Finazzi G, Ruggeri M, et al. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med 1995; 332:1132-1136.
29. Harrison CN, Campbell PJ, Buck G, et al. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med 2005; 353:33-45. The largest randomized study in essential thrombocythemia proves the superiority of hydroxyurea over anagrelide, both in combination with aspirin, in the treatment of high-risk essential thrombocythemia. The study showed that hydroxyurea combined with low-dose aspirin was associated with a lesser risk of arterial thrombosis, major hemorrhage, and transformation into myelofibrosis.
30. Rocca B, Ciabattoni G, Tartaglione R, et al. Increased thromboxane biosynthesis in essential thrombocythemia. Thromb Haemost 1995; 74:1225-1230.
31. Michiels JJ, Berneman ZN, Schroyens W, Van Vliet HH. Pathophysiology and treatment of platelet-mediated microvascular disturbances, major thrombosis and bleeding complications in essential thrombocythaemia and polycythaemia vera. Platelets 2004; 15:67-84.
32. Budde U, Schaefer G, Mueller N, et al. Acquired von Willebrand's disease in the myeloproliferative syndrome. Blood 1984; 64:981-985.
33. Passamonti F, Rumi E, Pungolino E, et al. Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. Am J Med 2004; 117:755-761. A large study with many helpful pieces of information about the natural history of essential thrombocythemia.
34. Wright CA, Tefferi A. A single institutional experience with 43 pregnancies in essential thrombocythemia. Eur J Haematol 2001; 66:152-159.
35. Tefferi A, Hanson CA, Inwards DJ. How to interpret and pursue an abnormal complete blood cell count in adults. Mayo Clin Proc 2005; 80:923-936.
36. Bennett JM. The myelodysplastic/myeloproliferative disorders: the interface. Hematol Oncol Clin North Am 2003; 17:1095-1100.
37. Thiele J, Kvasnicka HM, Diehl V, et al. Clinicopathological diagnosis and differential criteria of thrombocythemias in various myeloproliferative disorders by histopathology, histochemistry and immunostaining from bone marrow biopsies. Leukemia Lymphoma 1999; 33:207-218.
38. Rozman C, Giralt M, Feliu E, et al. Life expectancy of patients with chronic nonleukemic myeloproliferative disorders. Cancer 1991; 67:2658-2663.
39. Wolanskyj AP, Segovis CM, Schwager SM, et al. Essential thrombocythemia: beyond the first decade. Blood 2003; 102:920a.
40. Ruggeri M, Finazzi G, Tosetto A, et al. No treatment for low-risk thrombocythaemia: results from a prospective study. Br J Haematol 1998; 103:772-777.
41. Harrison CN. Essential thrombocythaemia: challenges and evidence-based management. Br J Haematol 2005; 130:153-165.
42. Vannucchi AM, Grossi A, Pancrazzi A, et al. PRV-1, erythroid colonies and platelet Mpl are unrelated to thrombosis in essential thrombocythaemia. Br J Haematol 2004; 127:214-219.
43. Chiusolo P, La Barbera EO, Laurenti L, et al. Clonal hemopoiesis and risk of thrombosis in young female patients with essential thrombocythemia. Exp Hematol 2001; 29:670-676.
44. Zamora L, Espinet B, Florensa L, et al. Clonality analysis by HUMARA assay in Spanish females with essential thrombocythemia and polycythemia vera. Haematologica 2005; 90:259-261.
45. Cortelazzo S, Viero P, Finazzi G, et al. Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia. J Clin Oncol 1990; 8:556-562.
46. Storen EC, Tefferi A. Long-term use of anagrelide in young patients with essential thrombocythemia. Blood 2001; 97:863-866.
47. Regev A, Stark P, Blickstein D, Lahav M. Thrombotic complications in essential thrombocythemia with relatively low platelet counts. Am J Hematol 1997; 56:168-172.
48. Silver RT. Interferon alfa: effects of long-term treatment for polycythemia vera. Semin Hematol 1997; 34:40-50.